NewAmsterdam Pharma Company (NAMS) Price & Analysis

Compare

239 Followers

NAMS Stock Chart & Stats

$38.27

-$0.03(-0.12%)

At close: Jan 08 4:00 PM EST

$38.27

-$0.03(-0.12%)

Day’s Range― - ―

52-Week Range$14.06 - $41.47

Previous CloseN/A

Volume118.30K

Average Volume (3M)1.20M

Market Cap

$4.34B

Enterprise Value$2.68B

Total Cash (Recent Filing)$702.95M

Total Debt (Recent Filing)$266.00K

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Mar 04, 2026

EPS Estimate

-0.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.61

Shares Outstanding113,390,800

10 Day Avg. Volume1,189,285

30 Day Avg. Volume1,202,333

Financial Highlights & Ratios

PEG Ratio-0.53

Price to Book (P/B)3.20

Price to Sales (P/S)53.22

P/FCF Ratio-15.23

Enterprise Value/Market Cap0.62

Enterprise Value/Revenue76.05

Enterprise Value/Gross Profit76.05

Enterprise Value/Ebitda-9.30

Forecast

1Y Price Target

$46.38

Price Target Upside21.19% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.47

Revenue Forecast (FY)$27.10M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe composite 4-point MACE will be the primary endpoint in PREVAIL, and the 21% 4-point MACE in BROADWAY significantly derisks the upcoming Phase III PREVAIL data.

EarningsShares are up roughly 8% following the earnings release, approaching recent all-time highs, which is attributed to continued strong execution ahead of key catalysts.

Regulatory ProgressMarketing authorization applications for obicetrapib and the fixed-dose combination of obicetrapib plus ezetimibe have been accepted for review by the EMA.

Bears Say

NewAmsterdam Pharma Company News

NewAmsterdam Pharma reports Q3 revenue $348,000, consensus $4.56M

“We remain acutely focused on our mission to deliver obicetrapib, as a novel, well-tolerated, and conveniently administered therapy...

20d ago

NAMS

Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on NAMS stock, giving a Buy rating...

14d ago

NAMS

Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages

Stifel Nicolaus analyst James Condulis has maintained their bullish stance on NAMS stock, giving a Buy rating on...

15d ago

NAMS

NewAmsterdam Pharma Reports Q3 2025 Financial Results

Newamsterdam Pharma Company N.V. ( ($NAMS) ) has released its Q3 earnings. Here is a breakdown of the...

18d ago

NAMS

Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments

William Blair analyst Matt Phipps has maintained their bullish stance on NAMS stock, giving a Buy rating today....

20d ago

NAMS

NewAmsterdam Pharma’s Promising Developments and EU Approval Prospects Drive Buy Rating

Analyst Serge Belanger from Needham maintained a Buy rating on NewAmsterdam Pharma Company and increased the price target...

20d ago

NAMS

Optimistic Buy Rating for NewAmsterdam Pharma: Strong Financials, Promising R&D, and Strategic Growth Initiatives

NewAmsterdam Pharma Company, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

20d ago

NAMS

NewAmsterdam Pharma Achieves Key EMA Regulatory Milestone

An update from NewAmsterdam Pharma Company ( ($NAMS) ) is now available. On November 5, 2025, NewAmsterdam Pharma...

20d ago

NAMS

NewAmsterdam Pharma’s Latest Study: A Game Changer for Metabolic Disorders?

Newamsterdam Pharma Company N.V. (($NAMS)) announced an update on their ongoing clinical study. Study Overview: NewAmsterdam Pharma is...

28d ago

NAMS

NewAmsterdam Pharma’s Antioxidant Study: A Potential Game Changer?

Newamsterdam Pharma Company N.V. (($NAMS)) announced an update on their ongoing clinical study. NewAmsterdam Pharma Company N.V. is...

28d ago

NAMS

NewAmsterdam Pharma’s VINCENT Study: A Promising Step in Cardiovascular Treatment

Newamsterdam Pharma Company N.V. (($NAMS)) announced an update on their ongoing clinical study. Study Overview: NewAmsterdam Pharma is...

29d ago

NAMS

NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis assumed coverage of NewAmsterdam Pharma (NAMS) with a Buy rating and $52 price...

1M ago

NAMS

NewAmsterdam Pharma price target raised to $50 from $42 at Citi

Citi raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $50 from $42 and keeps a Buy...

1M ago

NAMS

NewAmsterdam Pharma initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of NewAmsterdam Pharma (NAMS) with an Overweight rating and $45 price target The firm...

3M ago

NAMS

NAMS FAQ

What was NewAmsterdam Pharma Company’s price range in the past 12 months?

NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $41.47 in the past 12 months.

What is NewAmsterdam Pharma Company’s market cap?

NewAmsterdam Pharma Company’s market cap is $4.34B.

When is NewAmsterdam Pharma Company’s upcoming earnings report date?

NewAmsterdam Pharma Company’s upcoming earnings report date is Mar 04, 2026 which is in 99 days.

How were NewAmsterdam Pharma Company’s earnings last quarter?

NewAmsterdam Pharma Company released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.525 by -$0.085.

Is NewAmsterdam Pharma Company overvalued?

According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NewAmsterdam Pharma Company pay dividends?

NewAmsterdam Pharma Company does not currently pay dividends.

What is NewAmsterdam Pharma Company’s EPS estimate?

NewAmsterdam Pharma Company’s EPS estimate is -0.4.

How many shares outstanding does NewAmsterdam Pharma Company have?

NewAmsterdam Pharma Company has 113,390,800 shares outstanding.

What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?

NewAmsterdam Pharma Company reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.525. Following the earnings report the stock price went up 4.353%.

Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?

Currently, no hedge funds are holding shares in NAMS

NewAmsterdam Pharma Company Stock Smart Score

Neutral

Fundamentals

Return on Equity

-39.94%

Trailing 12-Months

Asset Growth

79.06%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

NewAmsterdam Pharma Company

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company (NAMS) Earnings & Revenues

Historic Earnings Reports

NAMS Stock 12 Month Forecast

Average Price Target

$46.38

▲(21.19% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","61":"$61","27.25":"$27.3","38.5":"$38.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,27.25,38.5,49.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.95,39.64615384615385,41.34230769230769,43.03846153846154,44.73461538461539,46.43076923076923,48.12692307692308,49.823076923076925,51.519230769230774,53.215384615384615,54.91153846153846,56.607692307692304,58.30384615384615,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.95,38.59846153846154,39.24692307692308,39.89538461538462,40.543846153846154,41.19230769230769,41.84076923076923,42.48923076923077,43.13769230769231,43.78615384615385,44.434615384615384,45.08307692307692,45.73153846153846,{"y":46.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.95,37.338461538461544,36.72692307692308,36.11538461538462,35.503846153846155,34.892307692307696,34.28076923076923,33.66923076923077,33.05769230769231,32.44615384615385,31.834615384615383,31.223076923076924,30.611538461538462,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.82,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >